Navigation Links
IntegriChain Announces Measurement of Retail Inventory(TM) (MRI) Analytic
Date:4/2/2009

New analytic offering provides pharmaceutical manufacturers with a highly reliable measure of inventory levels in the retail channel.

PRINCETON, N.J., April 2 /PRNewswire/ -- US Pharmaceutical manufacturers routinely struggle to accurately quantify the amount of product in the retail channel. This measurement affects a number of key aspects of financial reporting, such as: revenue recognition and returns accrual calculations, SOX compliance, forecasting and other critical financial planning functions. Unfortunately, the pharmaceutical manufacturer has very little visibility to where actual inventory levels are at any specific time. This lack of visibility to retail inventory levels forces pharmaceutical manufacturers to provide "best estimates" or "back of the envelope" calculations which cause significant angst with financial analysts and investors.

Recent industry trends indicate that retail "days on hand" inventories vary dramatically month-to-month and by individual retailer; exposing these critical financial computations to increased levels of potential error. Compounding this problem is the fact that many blockbuster drugs are coming off patent in the next few years, and pharmaceutical manufacturers are looking for ways to more accurately accrue for returns and provide auditable financial reserves for a new economy in the US pharmaceutical market.

Traditionally, most pharmaceutical manufacturers have relied upon doctor prescribing behavior data to determine demand, and have backed into retail inventories from this data. However, a growing number of PBMs are withholding their prescription information from vendors that estimate demand, and an increasing number of states are pursuing legislation to block prescription reporting. As national prescription demand data deteriorates and retail volatility increases, manufacturers' current approach to total pipeline measurement is becoming unsustainable.

IntegriChain, an information service provider to the pharmaceutical industry, has recently announced IntegriChain MRI(TM): Measurement of Retail Inventory; an analytic service which has been specifically designed to provide a highly accurate measurement of retail inventory capable of delivering calculations to +/- 2 days on hand (DOH). The MRI(TM) analytical service is an extension of the company's flagship Enriched Channel Sales(TM) information service which provides a highly accurate (>99%) view into downstream sales of pharmaceutical products into over 300,000 dispensing locations in the US, including all retail pharmacies, mass merchants, hospitals, clinics, long-term care, federal facilities, etc. The company has developed extensive intelligence on retail, wholesale and institution inventory patterns, and through its proprietary analytics provides an unparalleled level of transparency into inventory movement in the downstream market. "We see this as a watershed tool for financial reporting, planning and analysis functions within all US pharmaceutical manufacturers," states Kevin Leininger, chief executive of IntegriChain. "Most pharma companies are left 'in the dark' relative to their total pipeline measures, and we believe our solution offers them a high-confidence measure that they have not had heretofore."

The MRI(TM) service is available on a brand-by-brand basis immediately from IntegriChain and requires a subscription to Enriched Channel Sales(TM). The service is delivered via a standard Microsoft(R) interface and is offered on either monthly or weekly frequency intervals.

About IntegriChain

IntegriChain, Inc. is an information services company which provides data collection, integration, enrichment, analysis and reporting of sales and inventory activity exclusively for the pharmaceutical industry. IntegriChain enables manufacturers to improve sales performance and total pipeline measurement by maximizing transparency and accountability in the down-stream supply chain. IntegriChain's Enriched Channel Sales(TM) and advanced analytics are transforming the role of channel data within key pharmaceutical application areas including new product launch, finance, sales forecasting and demand analysis.


'/>"/>
SOURCE IntegriChain, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. IntegriChain Enlists Ed Casey and Associates to Drive Counterfeit and Diversion Monitoring Service
2. Medical Nurse Training, Inc. Announces the Launch of Medicalnursetraining.com
3. Anesiva Announces Going Concern Opinion and Nasdaq Notice
4. BD Announces Live Webcast of Second Fiscal Quarter Earnings Conference Call
5. Novavax Announces Closing of $11 Million Common Stock Sale to Subsidiary of Cadila Pharmaceuticals
6. HealthSouth Announces Date of 2009 First Quarter Earnings Conference Call
7. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
8. Misonix Announces New Distribution Agreement for Belgium and Luxembourg
9. Waters Corporation Announces the Purchase of UPLC/MS Systems by the National Cancer Institute for Advanced Metabolomics Research
10. Harvest Technologies Announces Interim Study Results From Critical Limb Ischemia Trial in Chennai India
11. BPO Management Services Announces Financial Results for Fourth Quarter and Full Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , ... February 23, 2017 , ... ... with a clinician-based audience, will be participating in Rare Disease Day events, hosted ... D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss ... WE TV’s “Mama June: From Not to Hot,” which will begin airing on February ... Shannon, known to millions from the 2012 reality television series, “Here Comes Honey Boo ...
(Date:2/23/2017)... ... 23, 2017 , ... Rosica Communications, a national PR ... media management, corporate communications, SEO and cause marketing, is opening an office in ... Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... host a diverse symposium on “Doping in Sport: How the Culture Might ... Richter & Hampton LLP. The symposium will be held at Pepperdine University in ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... CITY, Calif., Feb. 23, 2017 Nevro Corp. (NYSE: ... evidence-based solutions for the treatment of chronic pain, today reported ... December 31, 2016. 2016 Accomplishment & Highlights: ... full year 2016, an increase of 228% as reported, over ... for 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology: